Arovella Therapeutics Study Demonstrates CLDN18.2 CAR-T Cells Eliminate Pancreatic Cancer Cells, Shares Jump Over 13%

MT Newswires Live

2025/10/02

Arovella Therapeutics (ASX:ALA) confirmed the functionality of its claudin 18.2 (CLDN18.2)-targeting chimeric antigen receptor by demonstrating that CLDN18.2 chimeric antigen receptor-T (CAR-T) cells eliminate pancreatic cancer cells that express CLDN18.2 in a proof-of-concept in vitro study, according to a Thursday Australian bourse filing.

Arovella's chimeric antigen receptor design is based on the patent-protected CLDN18.2 antigen-binding sequences of the SPX-101 monoclonal antibody, for which the firm has an exclusive license for use in cell therapies.

The study was performed at the University of North Carolina. The human pancreatic adenocarcinoma cell line, PaTu8892S, which expresses CLDN18.2, was selected as a model cell line for this study. CLDN18.2 CAR-T cells, generated from three independent donors, were cultured in vitro with twice the number of PaTu8892S cells for three days. After this, the degree of cytotoxicity was measured.

The firm's shares jumped over 13% in recent trading on Thursday.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2572672375"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2572672375\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2572672375?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-02 10:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2572672375","market":"hk","top_or_hot":-1,"title":"Arovella Therapeutics Study Demonstrates CLDN18.2 CAR-T Cells Eliminate Pancreatic Cancer Cells, Shares Jump Over 13%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ARVEF\">Arovella Therapeutics</a> (ASX:ALA) confirmed the functionality of its claudin 18.2 (CLDN18.2)-targeting chimeric antigen receptor by demonstrating that CLDN18.2 chimeric antigen receptor-T (CAR-T) cells eliminate pancreatic cancer cells that express CLDN18.2 in a proof-of-concept in vitro study, according to a Thursday Australian bourse filing.</p><p>Arovella's chimeric antigen receptor design is based on the patent-protected CLDN18.2 antigen-binding sequences of the SPX-101 monoclonal antibody, for which the firm has an exclusive license for use in cell therapies.</p><p>The study was performed at the University of North Carolina. The human pancreatic adenocarcinoma cell line, PaTu8892S, which expresses CLDN18.2, was selected as a model cell line for this study. CLDN18.2 CAR-T cells, generated from three independent donors, were cultured in vitro with twice the number of PaTu8892S cells for three days. After this, the degree of cytotoxicity was measured.</p><p>The firm's shares jumped over 13% in recent trading on Thursday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arovella Therapeutics Study Demonstrates CLDN18.2 CAR-T Cells Eliminate Pancreatic Cancer Cells, Shares Jump Over 13%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArovella Therapeutics Study Demonstrates CLDN18.2 CAR-T Cells Eliminate Pancreatic Cancer Cells, Shares Jump Over 13%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-10-02 10:21</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ARVEF\">Arovella Therapeutics</a> (ASX:ALA) confirmed the functionality of its claudin 18.2 (CLDN18.2)-targeting chimeric antigen receptor by demonstrating that CLDN18.2 chimeric antigen receptor-T (CAR-T) cells eliminate pancreatic cancer cells that express CLDN18.2 in a proof-of-concept in vitro study, according to a Thursday Australian bourse filing.</p><p>Arovella's chimeric antigen receptor design is based on the patent-protected CLDN18.2 antigen-binding sequences of the SPX-101 monoclonal antibody, for which the firm has an exclusive license for use in cell therapies.</p><p>The study was performed at the University of North Carolina. The human pancreatic adenocarcinoma cell line, PaTu8892S, which expresses CLDN18.2, was selected as a model cell line for this study. CLDN18.2 CAR-T cells, generated from three independent donors, were cultured in vitro with twice the number of PaTu8892S cells for three days. After this, the degree of cytotoxicity was measured.</p><p>The firm's shares jumped over 13% in recent trading on Thursday.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"半新股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2572672375","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2572672375","pubTimestamp":1759371693,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Arovella Therapeutics  confirmed the functionality of its claudin 18.2 -targeting chimeric antigen receptor by demonstrating that CLDN18.2 chimeric antigen receptor-T  cells eliminate pancreatic cancer cells that express CLDN18.2 in a proof-of-concept in vitro study, according to a Thursday Australian bourse filing.Arovella's chimeric antigen receptor design is based on the patent-protected CLDN18.2 antigen-binding sequences of the SPX-101 monoclonal antibody, for which the firm has an exclusive license for use in cell therapies.The study was performed at the University of North Carolina. The human pancreatic adenocarcinoma cell line, PaTu8892S, which expresses CLDN18.2, was selected as a model cell line for this study. CLDN18.2 CAR-T cells, generated from three independent donors, were cultured in vitro with twice the number of PaTu8892S cells for three days. After this, the degree of cytotoxicity was measured.The firm's shares jumped over 13% in recent trading on Thursday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK7096":"制药","BK4022":"陆运","BK4230":"旅客陆运","BK4139":"生物科技","CAR":"安飞士","ALA.AU":"AROVELLA THERAPEUTICS LTD","BK4007":"制药","LENZ":"Therapeutics"},"translate_title":"Arovella Therapeutics研究证明CLDN18.2 CAR-T细胞可消除胰腺癌细胞，股价大涨超13%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"CAR":1.5,"ALA.AU":1},"content_text":"Arovella Therapeutics (ASX:ALA) confirmed the functionality of its claudin 18.2 (CLDN18.2)-targeting chimeric antigen receptor by demonstrating that CLDN18.2 chimeric antigen receptor-T (CAR-T) cells eliminate pancreatic cancer cells that express CLDN18.2 in a proof-of-concept in vitro study, according to a Thursday Australian bourse filing.Arovella's chimeric antigen receptor design is based on the patent-protected CLDN18.2 antigen-binding sequences of the SPX-101 monoclonal antibody, for which the firm has an exclusive license for use in cell therapies.The study was performed at the University of North Carolina. The human pancreatic adenocarcinoma cell line, PaTu8892S, which expresses CLDN18.2, was selected as a model cell line for this study. CLDN18.2 CAR-T cells, generated from three independent donors, were cultured in vitro with twice the number of PaTu8892S cells for three days. After this, the degree of cytotoxicity was measured.The firm's shares jumped over 13% in recent trading on Thursday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}